entertainment -WSS

entertainment

author：explore 2025-09-30 23:11:02 - browse：94

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： JPM 2024: Verve Therapeutics looks to mainstream genome editing

leisure time

WSS

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Readout LOUD podcast: live from JPM 2024

JPM 2024: Nvidia claims we're in biological revolution. Are we?

IRA could hurt research into orphan drugs for rare diseases

Health and fitness trackers are measuring the wrong things

focus

entertainment

leisure time

The high cost of giving birth even with insurance

Heart disease and mental health: A look at cardiac psychology

What does generative AI mean for health care? We asked experts

FDA proposes changes to key medical devices approval pathway

State Dept. review finds Biden bears some blame for Afghanistan failures

Health and fitness trackers are measuring the wrong things

State Dept. review finds Biden bears some blame for Afghanistan failures

The SUPPORT Act is critical to fighting the opioid crisis

Medicare proposal to cover medical devices draws a mixed reaction

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Wikipedia

Hospitals consider fixing cancer drug shortages on their own

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Acelyrin, a rare IPO success, stumbles in its first big test

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Will the IRA bring competition to the biologics market?

focus

focus

leisure time

Wikipedia